Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01102803 · ClinicalTrials.gov registry record · Phase 3
D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia
A Phase 3 study, sponsored by Southern Methodist University.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT01102803 is a Phase 3 study that has completed, run by Southern Methodist University. The registered enrollment target is 40 participants.
The verdict
NCT01102803, a Phase 3 study, has completed, sponsored by Southern Methodist University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the utility of post-session administration of D-cycloserine to enhance fear extinction in a sample of people with acrophobia who will be treated with CBT.
Interventions
- DRUG Placebo
- DRUG D-Cycloserine
- BEHAVIORAL Individual Cognitive Behavioral Therapy (CBT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01102803
The ClinicalTrials.gov registry entry for NCT01102803 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southern Methodist University, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01102803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01102803 about?
NCT01102803 is a clinical study titled "D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia". The purpose of this study is to investigate the utility of post-session administration of D-cycloserine to enhance fear extinction in a sample of people with acrophobia who will be treated with CBT.
What is the current status of trial NCT01102803?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2010-04. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01102803?
The interventions under investigation include: Placebo (DRUG), D-Cycloserine (DRUG), Individual Cognitive Behavioral Therapy (CBT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT01102803?
This trial is sponsored by Southern Methodist University, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.